443 related articles for article (PubMed ID: 16234113)
1. [Diagnostic value of combined detection of TPS, CA153 and CEA in breast cancer].
Zheng H; Luo RC
Di Yi Jun Yi Da Xue Xue Bao; 2005 Oct; 25(10):1293-4, 1298. PubMed ID: 16234113
[TBL] [Abstract][Full Text] [Related]
2. [Diagnostic value of combined detection of TPS, NSE and CEA in lung cancer].
Zheng H; He BF; Luo RC
Di Yi Jun Yi Da Xue Xue Bao; 2003 Feb; 23(2):165-6. PubMed ID: 12581971
[TBL] [Abstract][Full Text] [Related]
3. Serum tumour markers CEA, AFP, CA 15-3, TPS and Neu in diagnosis of breast cancer.
Eskelinen M; Kataja V; Hämäläinen E; Kosma VM; Penttilä I; Alhava E
Anticancer Res; 1997; 17(2B):1231-4. PubMed ID: 9137478
[TBL] [Abstract][Full Text] [Related]
4. [Clinical study of serum tissue polypeptide-specific antigen in breast cancer].
Zheng H; He BF; Luo RC; You CX; Mai GF; Lu HF
Di Yi Jun Yi Da Xue Xue Bao; 2003 Aug; 23(8):823-5. PubMed ID: 12919909
[TBL] [Abstract][Full Text] [Related]
5. Serum tissue polypeptide specific antigen (TPS) in breast cancer patients: comparison with CA 15.3 and CEA.
Willsher PC; Beaver J; Blamey RW; Robertson JF
Anticancer Res; 1995; 15(4):1609-11. PubMed ID: 7654057
[TBL] [Abstract][Full Text] [Related]
6. [Clinical and prognostic significance of preoperative serum CA153, CEA and TPS levels in patients with primary breast cancer].
Chen Y; Zheng YH; Lin YY; Hu MH; Chen YS
Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):842-6. PubMed ID: 22335950
[TBL] [Abstract][Full Text] [Related]
7. Clinical value of TPS, CEA and CA 15-3 in breast cancer patients.
Blijlevens NM; Oosterhuis WP; Oosten HR; Mulder NH
Anticancer Res; 1995; 15(6B):2711-6. PubMed ID: 8669851
[TBL] [Abstract][Full Text] [Related]
8. [Clinical value of combined detection of LDH, TPS, CEA and beta2-MG in patients with non- Hodgkin's lymphoma].
Chen W; Luo RC; Fan WW; Ma SD
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Feb; 26(2):227-8, 230. PubMed ID: 16503538
[TBL] [Abstract][Full Text] [Related]
9. Combined measurement of serum sialyl Lewis X with serum CA15-3 in breast cancer patients.
Kurebayashi J; Nomura T; Hirono M; Okubo S; Udagawa K; Shiiki S; Ikeda M; Nakashima K; Tanaka K; Sonoo H
Jpn J Clin Oncol; 2006 Mar; 36(3):150-3. PubMed ID: 16520359
[TBL] [Abstract][Full Text] [Related]
10. Determination of serum tumor markers TPS and CA 15-3 during monitoring of treatment in metastatic breast cancer patients.
Schuurman JJ; Bong SB; Einarsson R
Anticancer Res; 1996; 16(4B):2169-72. PubMed ID: 8694538
[TBL] [Abstract][Full Text] [Related]
11. [Clinical value of combined determination of serum and pleural effusion level of CEA,CYFRA21-1, TPS in the diagnosis of lung cancer].
Huang F; Wang XL; Yang L; Yin BX; Geng Y; Li TT
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Apr; 24(4):370-2. PubMed ID: 18394347
[TBL] [Abstract][Full Text] [Related]
12. TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients.
Giai M; Roagna R; Ponzone R; Biglia N; Sgro L; Perona M; Sismondi P
Anticancer Res; 1996; 16(2):875-81. PubMed ID: 8687144
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up study in breast cancer patients using serum tumor markers CEA and CA 15-3.
Lumachi F; Brandes AA; Boccagni P; Polistina F; Favia G; D'Amico DF
Anticancer Res; 1999; 19(5C):4485-9. PubMed ID: 10650797
[TBL] [Abstract][Full Text] [Related]
14. Comparison of TPS with CEA and CA 15.3 in follow-up of Chinese breast cancer patients.
Hu XC; Day W; Jones B; Loo WT; Chow LW
Anticancer Res; 2002; 22(3):1865-8. PubMed ID: 12168883
[TBL] [Abstract][Full Text] [Related]
15. [Significance of combined determination of CK19mRNA, carcinoembryanic antigen, neuron-specific enolase, and tissue polypeptide antigen in peripheral blood of patients with lung cancer].
Pan QR; Zhang X; Xu ZF; Zheng S
Ai Zheng; 2002 Feb; 21(2):196-9. PubMed ID: 12479076
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of CEA and CA 15-3 in the follow up of invasive breast cancer.
Sütterlin M; Bussen S; Trott S; Caffier H
Anticancer Res; 1999; 19(4A):2567-70. PubMed ID: 10470196
[TBL] [Abstract][Full Text] [Related]
17. A prospective study of tissue polypeptide specific antigen (TPS) in breast cancer diagnosis.
Eskelinen M; Hippeläinen M; Salmela E; Paajanen H; Alhava E; Syrjänen K
Anticancer Res; 1992; 12(6B):2033-6. PubMed ID: 1295446
[TBL] [Abstract][Full Text] [Related]
18. [Detection of serum S100 protein and tissue polypeptide-specific antigen for diagnosis and treatment of breast cancer].
Luo RC; He XB; Cai HB; Li AM
Di Yi Jun Yi Da Xue Xue Bao; 2004 Jan; 24(1):102-4. PubMed ID: 14724113
[TBL] [Abstract][Full Text] [Related]
19. Chemiluminometric determination of tissue polypeptide antigen (TPA), cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA) in comparison with vascular endothelial growth factor (VEGF) in follow-up of breast cancer.
Findeisen R; Albrecht S; Richter B; Deutschmann K; Zimmermann T; Distler W
Luminescence; 2000; 15(5):283-9. PubMed ID: 11038485
[TBL] [Abstract][Full Text] [Related]
20. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
